These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21596226)

  • 1. In vitro activity of tigecycline against extended-spectrum β-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study.
    Silva-Sanchez J; Reyna-Flores F; Velazquez-Meza ME; Rojas-Moreno T; Benitez-Diaz A; Sanchez-Perez A;
    Diagn Microbiol Infect Dis; 2011 Jun; 70(2):270-3. PubMed ID: 21596226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Lu CT; Chuang YC; Sun W; Liu YC; Cheng YJ; Lu PL; Chen CM; Hsu GJ; Jang TN; Lee CM; Chiang PC; Shi ZY; Wang LS; Kung HC; Lin HC; Liao CH; Liu JW; Huang CH; Tsao SM; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S179-83. PubMed ID: 19013351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.
    Ku YH; Chuang YC; Yu WL
    J Microbiol Immunol Infect; 2008 Aug; 41(4):332-6. PubMed ID: 18787741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
    Morosini MI; García-Castillo M; Coque TM; Valverde A; Novais A; Loza E; Baquero F; Cantón R
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2695-9. PubMed ID: 16870760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methicillin-resistant staphylococci (MRS) and extended-spectrum beta-lactamases (ESBL)-producing Enterobacteriaceae in companion animals: nosocomial infections as one reason for the rising prevalence of these potential zoonotic pathogens in clinical samples.
    Wieler LH; Ewers C; Guenther S; Walther B; Lübke-Becker A
    Int J Med Microbiol; 2011 Dec; 301(8):635-41. PubMed ID: 22000738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum beta-lactamase-producing Escherichia coli in Granada, Spain.
    Sorlózano A; Gutiérrez J; Salmerón A; Luna JD; Martínez-Checa F; Román J; Piédrola G
    Int J Antimicrob Agents; 2006 Dec; 28(6):532-6. PubMed ID: 17045785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of tigecycline against metallo-beta-lactamase-producing Enterobacteriaceae.
    Pliatsika V; Afkou Z; Protonotariou E; Sofianou D
    J Antimicrob Chemother; 2007 Dec; 60(6):1406-7. PubMed ID: 17962216
    [No Abstract]   [Full Text] [Related]  

  • 9. Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England.
    Hope R; Warner M; Potz NA; Fagan EJ; James D; Livermore DM
    J Antimicrob Chemother; 2006 Dec; 58(6):1312-4. PubMed ID: 17035342
    [No Abstract]   [Full Text] [Related]  

  • 10. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009).
    Sader HS; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Feb; 69(2):223-7. PubMed ID: 21251571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus.
    Rose WE; Poppens PT
    J Antimicrob Chemother; 2009 Mar; 63(3):485-8. PubMed ID: 19109338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae and trends in antibiotic consumption in a county of Sweden.
    Ostholm-Balkhed A; Tärnberg M; Nilsson M; Johansson AV; Hanberger H; Monstein HJ; Nilsson LE
    Scand J Infect Dis; 2010 Dec; 42(11-12):831-8. PubMed ID: 20608768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
    J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.
    Fritsche TR; Strabala PA; Sader HS; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):209-13. PubMed ID: 16105566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-spectrum beta-lactamase-producing organisms.
    Falagas ME; Karageorgopoulos DE
    J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
    Mendes RE; Rhomberg PR; Bell JM; Turnidge JD; Sader HS
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):415-25. PubMed ID: 19249175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from respiratory tract sources.
    Hawser SP
    Int J Antimicrob Agents; 2010 Apr; 35(4):414-5. PubMed ID: 20137900
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002.
    Bouchillon SK; Johnson BM; Hoban DJ; Johnson JL; Dowzicky MJ; Wu DH; Visalli MA; Bradford PA
    Int J Antimicrob Agents; 2004 Aug; 24(2):119-24. PubMed ID: 15288309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.